Combined xIL-6R and urocortin-2 treatment restores mdx diaphragm muscle force

Simple item page
dc.check.date2018-05-29
dc.check.infoAccess to this article is restricted until 12 months after publication by request of the publisher.en
dc.contributor.authorManning, Jennifer
dc.contributor.authorBuckley, Maria M.
dc.contributor.authorO'Halloran, Ken D.
dc.contributor.authorO'Malley, Dervla
dc.contributor.funderUniversity College Corken
dc.contributor.funderMuscular Dystrophy Ireland
dc.date.accessioned2017-08-24T09:26:48Z
dc.date.available2017-08-24T09:26:48Z
dc.date.issued2017-05-29
dc.date.updated2017-08-24T09:14:02Z
dc.description.abstractIntroduction: Duchenne muscular dystrophy (DMD) is characterized by progressive muscle degeneration leading to immobility, respiratory failure, and premature death. As chronic inflammation and stress are implicated in DMD pathology, the efficacy of an anti-inflammatory and anti-stress intervention strategy in ameliorating diaphragm dysfunction was investigated. Methods: Diaphragm muscle contractile function was compared in wild-type and dystrophin-deficient mdx mice treated with saline, anti-interleukin-6 receptor antibodies (xIL-6R), the corticotrophin-releasing factor receptor 2 (CRFR2) agonist, urocortin 2, or both xIL-6R and urocortin 2. Results: Combined treatment with xIL-6R and urocortin 2 rescued impaired force in mdx diaphragms. Mechanical work production and muscle shortening was also improved by combined drug treatment. Conclusions: Treatment which neutralizes peripheral IL-6 signaling and stimulates CRFR2 recovers force-generating capacity and the ability to perform mechanical work in mdx diaphragm muscle. These findings may be important in the search for therapeutic targets in DMD.en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationManning, J., Buckley, M. M., O'Halloran, K. D. and O'Malley, D. (2017) 'Combined xIL-6R and urocortin-2 treatment restores mdx diaphragm muscle force', Muscle and Nerve. doi:10.1002/mus.25644en
dc.identifier.doi10.1002/mus.25644
dc.identifier.endpage7en
dc.identifier.issn0148-639X
dc.identifier.issn1097-4598
dc.identifier.journaltitleMuscle and Nerveen
dc.identifier.startpage1en
dc.identifier.urihttps://hdl.handle.net/10468/4521
dc.language.isoenen
dc.publisherJohn Wiley & Sons, Inc.en
dc.rights© 2017, Wiley Periodicals, Inc. This is the peer reviewed version of the following article: Manning, J., Buckley, M. M., O'Halloran, K. D. and O'Malley, D. (2017) 'Combined xIL-6R and urocortin-2 treatment restores mdx diaphragm muscle force', Muscle and Nerve, which has been published in final form at http://dx.doi.org/10.1002/mus.25644. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.en
dc.subjectCorticotrophin-releasing factoren
dc.subjectDiaphragmen
dc.subjectInterleukin-6en
dc.subjectmdxen
dc.subjectMonoclonalen
dc.subjectUrocortin 2en
dc.titleCombined xIL-6R and urocortin-2 treatment restores mdx diaphragm muscle forceen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2732.pdf
Size:
1.11 MB
Format:
Adobe Portable Document Format
Description:
Accepted Version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Physiology - Journal Articles